Physician profile
Heidi A Worth
NPI 1417453309
$1,765.37
in general payments reported to CMS, 2019-2025
33 companies · $99.73 in 2025
The $99.73 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.13 · 2022: $486 · 2023: $645 · 2024: $522 · 2025: $99.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,100 · Education: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,100.24 |
| Education | $166.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $172.24 | 2022-2023 | Jakafi, Monjuvi, Pemazyre |
| Merck Sharp & Dohme LLC | $144.29 | 2022-2024 | Keytruda, Welireg, Lynparza |
| Pfizer INC. | $137.66 | 2024 | |
| Janssen Biotech, INC. | $129.51 | 2022-2024 | Rybrevant, Tecvayli, Darzalex |
| Celgene Corporation | $115.30 | 2023-2025 | Abecma, Reblozyl |
| Amgen INC. | $114.65 | 2022-2023 | Xgeva, Vectibix, Nplate |
| E.R. Squibb & Sons, L.L.C. | $101.02 | 2023-2025 | Opdivo, Abecma |
| Genzyme Corporation | $86.46 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $81.34 | 2022-2023 | Soliris, Ultomiris |
| Lilly USA, LLC | $73.74 | 2022-2024 | Verzenio, Jaypirca, Retevmo |
| Genentech USA, INC. | $68.69 | 2022-2024 | Venclexta, Perjeta, Kadcyla |
| Daiichi Sankyo INC. | $60.70 | 2022-2023 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $54.38 | 2023-2024 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $46.60 | 2022-2024 | Alunbrig |
| Abbvie INC. | $40.98 | 2022-2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $34.38 | 2022-2023 | Tazverik |
| Novartis Pharmaceuticals Corporation | $28.63 | 2024 | |
| Sobi, INC | $26.41 | 2023 | |
| Janssen Pharmaceuticals, INC | $22.68 | 2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $22.12 | 2024 | Tagrisso |
| Emd Serono, INC. | $21.30 | 2024 | |
| Jazz Pharmaceuticals INC. | $19.60 | 2022 | |
| Puma Biotechnology, INC. | $19.14 | 2023 | |
| Eisai INC. | $16.29 | 2023 | |
| Myriad Genetic Laboratories, INC. | $16.18 | 2024 | Myrisk |
| Astellas Pharma US INC | $16.15 | 2024 | |
| Pharmacosmos Therapeutics INC. | $15.24 | 2023 | Monoferric |
| Deciphera Pharmaceuticals INC. | $13.66 | 2022 | |
| Exelixis INC. | $13.54 | 2022 | |
| Gilead Sciences, INC. | $13.33 | 2023 | Trodelvy |
| Seagen INC. | $13.27 | 2023 | Padcev |
| Mylan Specialty L.P. | $13.13 | 2019 | |
| Kyowa Kirin, INC. | $12.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Worth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.